|
|
|
| Discussion on the potential mechanism of Simiao Powder in the treatment of gouty arthritis based on network pharmacology |
| RONG Weiming1 YUAN Changshen2 DUAN Kan2 MEI Qijie2 GUO Jinrong2 LU Zhixian1 |
1.Graduate School, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530000, China;
2.the Third Department of Orthopedics, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530023, China |
|
|
|
Abstract Objective To explore the potential mechanism of Simiao Powder in the treatment of gouty arthritis by network pharmacology approach. Methods The effective components and their targets of Simiao Powder were screened by the traditional Chinese medicine systems pharmacology database and analysis platform. Disease-related genes were screened using GeneGards and OMIM database, and target genes were obtained by intersection with drug targets. Then GO and KEGG enrichment analysis were performed for the target genes, and proteinprotein interaction network of the target genes was constructed using STRING database and key genes were screened out. Finally, the drug-gene-pathway network was constructed. Results There were 40 active components in Simiao Powder acting on 197 targets, 215 genes related to gouty arthritis, and 27 target genes were obtained through the intersection, which were mainly enriched in 622 GO entries and 109 signaling pathways such as IL-17 and TNF obtained by KEGG pathway analysis. Five genes, including PTGS2, PPARG and CCL2 were key genes. Conclusion Simiao Powder effectively controls the development of gouty arthritis mainly through PTGS2, PPARG, CCL2 and other genes as well as IL-17 and TNF signaling pathways.
|
|
|
|
|
|
[1] 冯文文，崔岱，杨涛.《中国高尿酸血症与痛风诊疗指南（2019）》要点解读[J].临床内科杂志，2020，37（7）：528-531.
[2] Ene-Stroescu D，Gorbien MJ. Gouty arthritis. A primer on late-onset gout [J]. Geriatrics，2005，60（7）：24-31.
[3] 刘振葳，曲凡，牛莉，等.痛风中医证候学研究现状[J].中华中医药杂志，2019，34（6）：2626-2628.
[4] 袁晓静，沈丕安，戴琪萍，等.痛风性关节炎的中医治疗进展[J].现代生物医学进展，2014，14（28）：5582-5585.
[5] 黎创，吴一帆.黄春林治疗高尿酸血症及痛风经验分析[J].河北中医，2012，34（9）：1287-1288.
[6] 周弘征，邱晓堂.邱晓堂教授治疗高尿酸血症临床经验[J].中国医药导报，2018，15（18）：136-139.
[7] 巫喜燕，曾芬，徐权胜.四妙散加味联合九味双柏膏治疗痛风性关节炎湿热痹阻证的临床效果[J].中国当代医药，2019，26（1）：193-196.
[8] 杜明瑞，郭志忠，冯福海.四妙散为主方治疗痛风性关节炎疗效与安全性的系统评价[J].中国实验方剂学杂志，2015，21（13）：212-216.
[9] 茅华杰.槲皮素对骨性关节炎的作用及其机制研究[D].杭州：浙江大学，2019.
[10] 黄敬群，刘久红，李伟中，等.槲皮素对急性痛风性关节炎大鼠的治疗作用及其对肝功能的影响[J].山东医药，2015，55（28）：27-29.
[11] 王亚杰.桑色素对酪氨酸酶、黄嘌呤氧化酶抑制机理的探讨[D].南昌：南昌大学，2015.
[12] 孙广瀚，刘健，万磊，等.急性痛风性关节炎致炎蛋白的蛋白质组学研究[J].浙江大学学报：医学版，2020，49（6）：743-749.
[13] Schlesinger N. Difficult-to-treat gouty arthritis：a disease warranting better management [J]. Drugs，2011，71（11）：1413-1439.
[14] 滕方舟，蔡唐彦，郭洁梅，等.痛风宁对急性痛风性关节炎模型大鼠IL-1β，TNF-α及NALP3炎性体的影响[J].中国实验方剂学杂志，2018，24（17）：120-125.
[15] Amatya N，Garg AV，Gaffen SL. IL-17 Signaling：The Yin and the Yang [J]. Trends Immunol，2017，38（5）：310-322.
[16] Liu Y，Zhao Q，Yin Y，et al. Serum levels of IL-17 are elevated in patients with acute gouty arthritis [J]. Biochem Biophys Res Commun，2018，497（3）：897-902.
[17] Raucci F，Iqbal AJ，Saviano A，et al. IL-17A neutralizing antibody regulates monosodium urate crystal-induced gouty inflammation [J]. Pharmacol Res，2019，147：104351.
[18] 丘创华，侯敢，黄迪南.TNF-α信号传导通路的分子机理[J].中国生物化学与分子生物学报，2007，23（6）：430-435.
[19] Hellmann J，Tang Y，Zhang MJ，et al. Atf3 negatively regulates Ptgs2/Cox2 expression during acute inflammation [J]. Prostaglandins Other Lipid Mediat，2015，116/117：49-56.
[20] 亓国锋，楚天舒，刘谓，等.加味四妙汤辅助治疗痛风性关节炎对RAGE、COX-2水平变化研究[J].中华中医药学刊，2021，39（1）：11-13.
[21] Wang RC，Jiang DM. PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines [J]. Genet Mol Res，2014，13（3）：6577-6581.
[22] Li B，Chen X，Jiang Y，et al. Title：CCL2promoter hypomethylation is associated with gout risk in Chinese Han male population [J]. Immunol Lett，2017，190：15-19.
[23] 徐晓辰，丁焕发，刘淑娟，等.血清IL-1β、IL-6、IL-18及TNF-α水平在急性痛风性关节炎镇痛治疗不同时间动态变化的研究[J].中国医学创新，2016，13（24）：4-10. |
|
|
|
